Masimo says the FDA cleared smartSedLine, an anesthesia-monitoring system; the company’s performance claims have yet to establish whether the device improves patient outcomes or lowers costs.
Masimo announced Nov. 18 that the Food and Drug Administration granted 510(k) clearance for smartSedLine, a system designed to monitor brain activity during anesthesia. The company says its enhanced Patient State Index algorithm responds faster during anesthesia induction and provides greater stability when electroencephalogram (EEG) power is low.
The clearance is a regulatory milestone, but it is not evidence by itself that the system improves patient outcomes or reduces healthcare spending. Masimo did not provide clinical results, cost information or estimates of how the device might affect complications, recovery times or hospital stays in the announcement summarized in available source material.
The distinction matters in a healthcare system where new devices can carry costs for hospitals and, ultimately, patients and payers. Faster or steadier monitoring could be useful to anesthesia teams, but the relevant test is whether it changes care in a measurable way. The available information does not answer that question.
Masimo said smartSedLine includes a new module and EEG sensor and is compatible with the company’s Root platform. It also described the clearance as its seventh FDA clearance in 2026. The company’s description of the system’s capabilities and the count of its clearances are company claims, not independent assessments of clinical benefit.
A 510(k) clearance generally means the FDA has found a device substantially equivalent to a legally marketed predicate device for its intended use. It is distinct from FDA approval through the premarket approval pathway, which is generally used for higher-risk devices. Neither regulatory route should be confused with proof that a technology lowers the total cost of care in routine practice.
A separate healthcare-related business announcement highlighted growth in services tied to insurance quality measures. Ash said it ranked No. 186 on the 2026 Deloitte Technology Fast 500 and grew 374% from 2022 to 2025. The company attributed its growth to demand from Medicare Advantage plans for HEDIS care-gap closure and to its white-label, AI-powered member-engagement model.
That attribution comes from Ash, which provides diagnostics and related services; it is not an independent finding that the company’s tools improved patients’ health or reduced Medicare spending. Deloitte’s broader report said honorees recorded revenue growth ranging from 97% to 66,330%, averaging 1,134%, and collectively added more than $91 billion in revenue from 2022 to 2025. Those figures describe company growth, not clinical value. The source material also contains conflicting Ash growth figures, so its reported 374% is best treated as the company’s own claim rather than reconciled with Deloitte’s ranking data.
The commercial incentives are worth watching. Medicare Advantage plans face pressure to document and close care gaps, while vendors have an incentive to sell tools that promise to support those efforts. Whether the approach benefits patients depends on more than activity or revenue: useful measures would include whether people receive needed care, whether health improves, and whether the service justifies its price.
The same evidence standard applies to new hospital technologies. FDA clearance can establish a regulatory basis for marketing, but patients and providers still need clear information about what a device does, what it costs and whether it produces better results than existing options. For smartSedLine, the announcement offers a technical rationale and a compatibility claim, but no disclosed outcome or cost comparison.
The next consequential evidence would be independent clinical data and real-world comparisons that show whether the system helps clinicians manage anesthesia more effectively and whether any improvement is worth its cost. Until then, the clearance marks permission to market—not a demonstrated bargain for patients or the healthcare system.

